Navigation Links
Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
Date:3/4/2013

Norwood, MA (PRWEB) March 04, 2013

Infinata’s BioPharm Insight released its Licensing League Tables Report for 4Q12 and YE12 to subscribers in mid-February. This report provides insight needed to evaluate market opportunities, market values and trends as well as competitive strategies.

The total volume and disclosed value of licensing agreements involving pharmaceutical products picked up in 4Q12. The quarter has seen 110 agreements with an aggregate disclosed value of USD 6,813m. That is an increase of 36% in volume and 42% in value from 3Q12, in which 81 agreements worth USD 4,787m were announced. The Antibody Program agreement between Menarini Group and Oxford BioTherapeutics was the largest deal in 4Q12, potentially valued at USD 1,035m.

Topping the charts in 4Q, legal advisor Wilson, Sonsini Goodrich & Rositi led the volume table having advised on eight transactions valued at USD 551m. While WilmerHale led the global value table for 4Q, having advised on six drug licensing agreements valued at USD 685m.

WilmerHale also led the global and North American volume tables for YE12 with 27 transactions valued at USD 1,283m, while tying with Cooley for the European volume tables, both having advised on eight transactions. Cooley also led the global and North American value tables for YE12 with 26 transactions valued at USD 4,280m and 25 transactions valued at USD 4,272m, respectively. Covington & Burling took the top spot for the European value table for YE12 having advised on seven agreements valued at USD 3,765m.

Access all of BioPharm Insight’s reports by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10476962.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
2. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
3. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
4. PDL BioPharma to Present at Two Upcoming Investor Conferences
5. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2013
8. Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
9. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
10. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
11. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
Breaking Biology News(10 mins):